Head and Neck Cancer SPORE at the University of Wisconsin

威斯康星大学头颈癌孢子

基本信息

批准号：
9768200
负责人：
PAUL M HARARI
金额：
$ 217.24万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-08-02 至 2021-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9768200
关键词：
Anatomy Animal Model Antibodies Appearance Biological Markers Biological Models Biometry Breathing Cancer Patient Cetuximab Clinical Research Clinical Trials Complex Coupled Data Deglutition Development Diagnosis Disease Dose ERBB3 gene Epidermal Growth Factor Receptor External Beam Radiation Therapy Future Genetically Engineered Mouse Goals Growth Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Head and neck structure Human Human Papillomavirus IGF1R gene Image Institution Laboratory Research Link Location Malignant Neoplasms Mediating Modeling Molecular Target Morbidity - disease rate Mus Mutation Newly Diagnosed Normal tissue morphology Outcome Pathology Pathway interactions Patient-Focused Outcomes Patients Peptides Phase I Clinical Trials Play Preclinical Testing Prognostic Marker Protein Tyrosine Kinase Quality of life Radiation Radiation Dose Unit Radiolabeled Recurrence Reporting Reproduction spores Research Research Personnel Research Project Grants Research Support Resistance Resources Role Scientist Severity of illness Signal Transduction Social Interaction Speech Testing Tissue Microarray Toxic effect Translating Translational Research Treatment outcome Tumor-Derived Universities Ursidae Family Wisconsin Xenograft Model Xenograft procedure anticancer research axl receptor tyrosine kinase base bench to bedside cancer therapy career career development clinical investigation conventional therapy design dosimetry head and neck cancer patient improved improved outcome mouse model multidisciplinary new therapeutic target novel novel therapeutics peptide drug predictive marker prognostic value programs receptor research and development research clinical testing response src-Family Kinases therapy resistant treatment strategy tumor tumor xenograft

项目摘要

PROJECT SUMMARY The Wisconsin Head and Neck SPORE is designed to promote translational laboratory and clinical research to improve overall outcome for patients with Head and Neck Cancer (HNC). This highly collaborative research links basic scientists with HNC clinicians to advance novel treatment strategies for this complex cancer popoulation. These patients bear a disproportionate burden from their cancers based on the critical anatomic location of the disease where treatment can compromise speech, swallow, and breathing function, in addition to creating significant alterations in physical appearance and capacity for social interaction. Efforts to improve cure rates must be carefully balanced with efforts to reduce treatment morbidity to enable enhanced overall quality of life for patients. The broad objectives of this SPORE are to: 1) Promote multidisciplinary translational research in HNC, 2) Improve overall survival and quality of life for patients with HNC, 3) Develop new animal model systems of HNC to test novel targeted therapy strategies, 4) Develop common resources (such as patient-derived tumor xenografts) to be shared across institutions to promote translational research, and 5) Translate promising new molecules developed at the University of Wisconsin through preclinical and clinical testing. The Wisconsin HN SPORE has designed four primary research projects. Project 1 will define and target molecular pathways that drive HNC using new mouse model systems, and identify biomarkers of prognostic value for clinical investigation. Project 2 will examine a novel, tumor-selective radiolabeled molecule developed at UW that internally targets HN tumors with radiation and shows potential to reduce toxicity from conventional treatment. Project 3 investigates molecular targeting of HNC with novel synstatin peptide therapeutics that disrupt signaling complexes coupled to receptor tyrosine kinases. Project 4 investigates the role of the receptor tyrosine kinase AXL in HNC therapy response and resistance to help design more effective future treatment strategies. The Wisconsin SPORE will support this research with three Cores (Administrative, Pathology and Biostatistics), a Career Enhancement Program and a Developmental Research Program.

项目摘要威斯康星州的头颈孢子旨在促进翻译实验室和临床研究改善头颈癌患者（HNC）的总体预后。这项高度协作的研究将基本科学家与HNC临床医生联系起来，以推进这种复杂癌症的新型治疗策略流行音乐。这些患者根据关键解剖学承担癌症的负担不成比例疾病的位置可以损害语音，吞咽和呼吸功能，此外在身体外观和社交互动的能力上产生重大变化。改进的努力必须仔细平衡治疗率，以减少治疗发病率以增强总体患者的生活质量。该孢子的广泛目标是：1）促进多学科翻译 HNC的研究，2）改善HNC患者的总体生存和生活质量，3）发展新动物 HNC测试新型目标治疗策略的模型系统，4）开发共同资源（例如患者衍生的肿瘤异种移植物）将在跨机构共享以促进转化研究，5）翻译有希望的新分子在威斯康星大学通过临床前和临床开发测试。威斯康星州HN Spore设计了四个主要研究项目。项目1将定义并靶向分子途径，该途径使用新的小鼠模型系统驱动HNC，并识别临床研究的预后价值。项目2将检查一种新型的肿瘤选择性放射性标记分子在UW开发的内部靶向具有辐射的HN肿瘤，并显示出降低毒性的潜力常规治疗。项目3研究了使用新型合成蛋白肽对HNC的分子靶向破坏信号传导复合物与受体酪氨酸激酶的疗法。项目4调查受体酪氨酸激酶AXL在HNC治疗反应和抗性中的作用，以帮助设计更有效未来的治疗策略。威斯康星州的孢子将通过三个核心支持这项研究（行政，病理学和生物统计学），一项职业增强计划和发展研究计划。